Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%Zacks Investment Research • 03/25/25
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli LillyCNBC • 03/25/25
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVOAccesswire • 03/25/25
NVO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - NVOAccesswire • 03/25/25
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S (NVO) of a Class Action Lawsuit and an Upcoming DeadlineAccesswire • 03/25/25
FINAL REMINDER NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Novo Nordisk A/S Investors to Participate in the Class Action LawsuitAccesswire • 03/25/25
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Lawsuit - NVOAccesswire • 03/24/25
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreAccesswire • 03/24/25
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVOAccesswire • 03/24/25
Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – NVOGlobeNewsWire • 03/24/25
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Hims & Hers Health PoppedThe Motley Fool • 03/24/25
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.Investors Business Daily • 03/24/25
FINAL NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Novo Nordisk A/S Investors to Join the Class Action LawsuitAccesswire • 03/24/25
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff CabraserAccesswire • 03/24/25
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offerPRNewsWire • 03/24/25
Novo Nordisk secures license to weight-loss drug candidate from China's United LabsReuters • 03/24/25
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonistGlobeNewsWire • 03/24/25
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sureCNBC • 03/24/25